Laidlaw Capital Markets is pleased to have acted as Co-Lead Manager on Delcath Systems' (DCTH) $22,000,000 financing and uplisting to NASDAQ. Laidlaw proudly served as the Sole Book Runner on the transaction.See Press Release
Laidlaw Capital Markets is pleased to announce today's pricing of a $70,000,000 Follow-On Offering for Arcturus Therapeutics (ARCT) around its Covid-19 vaccine and platform for other diseases. Laidlaw proudly served as Financial Advisor alongside Guggenheim, who was Sole-Book Runner on the transaction.
Podcast Series: A BRIGHTER FUTURE. Listen to our third session of the Laidlaw Five, our ongoing podcast series.
Podcast Series: A BRIGHTER FUTURE. Listen to our third session of the Laidlaw Five, our ongoing podcast series.
Laidlaw & Company enhances their Wealth Management offering with Envestnet | MoneyGuide NEW YORK, NY, UNITED STATES, March 11, 2020 /EINPresswire.com/ -- Laidlaw Wealth Management is pleased to announce it has chosen Envestnet, a leading provider of intelligent systems for wealth management and financial wellness, to provide Laidlaw advisors with access to their leading, Read More...
Watch Ann Marie Sastry's interview on CNBC's “Squawk Alley”. The CEO of AMESITE talks about her company and how artificial intelligence can be used in disease outbreaks and even to track the coronavirus. WATCH NOW
Laidlaw Capital Markets is pleased to announce today's pricing of a $21,750,000 Follow-On Offering for EyePoint Pharmaceuticals (EYPT). Laidlaw proudly served as Co-Manager alongside Guggenheim, who was Sole Book-Runner on the transaction. See full Press Release on Eyepoint Website
Laidlaw Capital Markets is pleased to announce today's pricing of a $10,000,000 Follow-On Offering for BioSig Technologies (BSGM). Laidlaw proudly served as the Sole Book Runner on the transaction. See full Press Release on BioSig Website
Laidlaw was proud to attend the closing bell ceremony at the NYSE yesterday. Defiance ETFs LLC is the first 5G ETF (NYSE Arca: FIVG) Alex Shtaynberger, Richard Calhoun and Keith Hassan from Laidlaw attended and were on the Podium. Watch as Matthew Bielski, Chief Executive Officer of Defiance ETFs rings The Closing Bell®. Defiance ETFs LLC Read More...
Laidlaw Capital Markets is pleased to announce today’s pricing of a $90,000,000 Follow-On Offering for Ziopharm Oncology (ZIOP). Laidlaw proudly served as Co-Manager alongside Jefferies, who was Sole-Book Runner on the transaction. See full Press Release on Ziopharm Website
© 2024 Copyright Laidlaw & Company (UK) Ltd. – All Rights Reserved. Laidlaw & Company (UK) Ltd., a FINRA broker-dealer registered in the United States, clears on a fully-disclosed basis through StoneX, a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited is authorized and regulated by the Financial Conduct Authority (FCA) in the UK (Firm Reference No: 537165).
© Copyright 2025 Laidlaw & Company (UK) Ltd. - All Rights Reserved. Laidlaw & Company (UK) Ltd., a FINRA broker-dealer registered in the United States, clears on a fully-disclosed basis through INTL FCStone Financial Inc., a member of the Securities Investor Protection Corporation (SIPC). Laidlaw & Company International Limited is authorized and regulated by the Financial Conduct Authority (FCA) in the UK (Firm Reference No: 537165).
Stay In Touch